Intercept Pharmaceuticals Inc (ICPT) 240.10 $ICPT
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Forest Laboratories Inc. (NYSE: FRX), Novatis AG (NYSE: NVS) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1162-100free.
Intercept Pharmaceuticals Larger Than S&P 500 Component PerkinElmer
at The Street - Mon Apr 14, 3:41PM CDT
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Intercept Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example PerkinElmer, Inc. ,...
Positive Results on Intercept Pharma's OCA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 3:30PM CDT
Intercept Pharma announced positive additional data from the phase III study on obeticholic acid.
Insider Trading Alert - PXLW, DORM And ICPT Traded By Insiders
at The Street - Mon Apr 14, 10:30AM CDT
Stocks with insider trader activity include PXLW, DORM and ICPT
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- ICPT
GlobeNewswire - Mon Apr 14, 3:00AM CDT
Pomerantz LLP has filed a class action lawsuit against Intercept Pharmaceutical, Inc. ("Intercept" or the "Company"
(Nasdaq:ICPT) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 1:14-cv-1373, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Intercept securities between January 9, 2014 and January 10, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...
Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session
GlobeNewswire - Sat Apr 12, 10:59AM CDT
-Notable Improvements on Key Endpoints as Early as Two Weeks After OCA Treatment Initiation
Intercept Announces Preclinical Data Demonstrating OCA's Potential Role in Preventing Complications of Cirrhosis
GlobeNewswire - Fri Apr 11, 8:17AM CDT
- Study Presented at EASL 2014 Named Best Oral Abstract in Basic Science at Annual Meeting -
UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against INTERCEPT PHARMACEUTICALS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of April 22, 2014 -- ICPT
GlobeNewswire - Thu Apr 10, 10:47AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company" (Nasdaq:ICPT) common stock between January 9, 2014 and January 10, 2014.
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.
Business Wire - Thu Apr 10, 9:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company" (NASDAQ:ICPT) that all purchasers of Intercept securities between January 9, 2014 and January 10, 2014, inclusive (the "Class Period" , have until April 22, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks
at The Street - Wed Apr 09, 9:06AM CDT
Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.
Intercept Pharma Prices 1M Share Offering, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:00PM CDT
Intercept Pharmaceuticals shares fell 9.61% after the company priced a public offering of 1 million shares of its common stock at $320.00 per share.
Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides
ACCESSWIRE - Tue Apr 08, 10:00AM CDT
WHITEFISH, MT / April 8, 2014 / There has been a disease steadily filling market headlines recently, and no; it's not cancer. It's fatty liver disease, particularly Non-alcoholic Fatty Liver Disease, or NAFLD, regarded by many as the most common non-communicable liver disease worldwide. The disease is a silent killer that often goes undetected until late stages, for which there are no FDA-approved treatments. Biotechs focusing on innovative therapies for varying stages of NAFLD are receiving plenty of deserved media coverage. Hepatology leaders in recent headlines include Intercept Pharmaceuticals, (NASDAQ: ICPT), Cempra, Inc. (NASDAQ: CEMP), MediciNova, Inc. (NASDAQ: MNOV), Galectin Therapeutics (NASDAQ: GALT) and Lumena Pharmaceuticals, a company preparing to go public.
NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK), GlaxoSmithKline plc (NYSE: GSK), and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Apr 04, 7:31PM CDT
Caution, not aggression, will be the rule next week, Cramer says.
Why Tesla Motors, Micron Technology, and Intercept Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Apr 04, 7:30PM CDT
The stock market closed the week with a substantial decline, as the Nasdaq Composite led the broader market down with a drop of more than 2%. High-flying momentum stocks suffered the brunt of the damage in the market Friday, and that, in part,...
Data From Intercept's Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014
GlobeNewswire - Fri Apr 04, 9:09AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced presentations of key data at the International Liver Congress 2014, the 49 Annual Meeting of the European Association for the Study of the Liver (EASL), being held in London, UK, at the ExCel Centre from April 9-13, 2014. Intercept will be exhibiting at booth #715 throughout the Congress.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Forest Laboratories Inc. (NYSE: FRX), Novatis AG (NYSE: NVS) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1162-100free.
Intercept Pharmaceuticals Larger Than S&P 500 Component PerkinElmer
at The Street - Mon Apr 14, 3:41PM CDT
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Intercept Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example PerkinElmer, Inc. ,...
Positive Results on Intercept Pharma's OCA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 3:30PM CDT
Intercept Pharma announced positive additional data from the phase III study on obeticholic acid.
Insider Trading Alert - PXLW, DORM And ICPT Traded By Insiders
at The Street - Mon Apr 14, 10:30AM CDT
Stocks with insider trader activity include PXLW, DORM and ICPT
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- ICPT
GlobeNewswire - Mon Apr 14, 3:00AM CDT
Pomerantz LLP has filed a class action lawsuit against Intercept Pharmaceutical, Inc. ("Intercept" or the "Company"
(Nasdaq:ICPT) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 1:14-cv-1373, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Intercept securities between January 9, 2014 and January 10, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...
Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session
GlobeNewswire - Sat Apr 12, 10:59AM CDT
-Notable Improvements on Key Endpoints as Early as Two Weeks After OCA Treatment Initiation
Intercept Announces Preclinical Data Demonstrating OCA's Potential Role in Preventing Complications of Cirrhosis
GlobeNewswire - Fri Apr 11, 8:17AM CDT
- Study Presented at EASL 2014 Named Best Oral Abstract in Basic Science at Annual Meeting -
UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against INTERCEPT PHARMACEUTICALS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of April 22, 2014 -- ICPT
GlobeNewswire - Thu Apr 10, 10:47AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company"
(Nasdaq:ICPT) common stock between January 9, 2014 and January 10, 2014. INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.
Business Wire - Thu Apr 10, 9:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company"
(NASDAQ:ICPT) that all purchasers of Intercept securities between January 9, 2014 and January 10, 2014, inclusive (the "Class Period" , have until April 22, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks
at The Street - Wed Apr 09, 9:06AM CDT
Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.
Intercept Pharma Prices 1M Share Offering, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:00PM CDT
Intercept Pharmaceuticals shares fell 9.61% after the company priced a public offering of 1 million shares of its common stock at $320.00 per share.
Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides
ACCESSWIRE - Tue Apr 08, 10:00AM CDT
WHITEFISH, MT / April 8, 2014 / There has been a disease steadily filling market headlines recently, and no; it's not cancer. It's fatty liver disease, particularly Non-alcoholic Fatty Liver Disease, or NAFLD, regarded by many as the most common non-communicable liver disease worldwide. The disease is a silent killer that often goes undetected until late stages, for which there are no FDA-approved treatments. Biotechs focusing on innovative therapies for varying stages of NAFLD are receiving plenty of deserved media coverage. Hepatology leaders in recent headlines include Intercept Pharmaceuticals, (NASDAQ: ICPT), Cempra, Inc. (NASDAQ: CEMP), MediciNova, Inc. (NASDAQ: MNOV), Galectin Therapeutics (NASDAQ: GALT) and Lumena Pharmaceuticals, a company preparing to go public.
NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK), GlaxoSmithKline plc (NYSE: GSK), and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Apr 04, 7:31PM CDT
Caution, not aggression, will be the rule next week, Cramer says.
Why Tesla Motors, Micron Technology, and Intercept Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Apr 04, 7:30PM CDT
The stock market closed the week with a substantial decline, as the Nasdaq Composite led the broader market down with a drop of more than 2%. High-flying momentum stocks suffered the brunt of the damage in the market Friday, and that, in part,...
Data From Intercept's Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014
GlobeNewswire - Fri Apr 04, 9:09AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced presentations of key data at the International Liver Congress 2014, the 49 Annual Meeting of the European Association for the Study of the Liver (EASL), being held in London, UK, at the ExCel Centre from April 9-13, 2014. Intercept will be exhibiting at booth #715 throughout the Congress.
